Shanghai Zerun Biotechnology Co., Ltd.
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Subsidiary
- Established
- 2003-05-07
- Employees
- -
- Market Cap
- -
- Website
- http://www.zerunbio.com
Long-term Follow-up of Bivalent Human Papillomavirus (HPV) Vaccine Study in Women
Active, not recruiting
- Conditions
- Cervical CancerVulvar CancerVaginal CancerCIN - Cervical Intraepithelial NeoplasiaHuman Papillomavirus Infection
- Interventions
- Biological: HPV-16/18 vaccineBiological: Placebo
- First Posted Date
- 2025-01-15
- Last Posted Date
- 2025-01-15
- Lead Sponsor
- Shanghai Zerun Biotechnology Co.,Ltd
- Target Recruit Count
- 5372
- Registration Number
- NCT06776055
- Locations
- 🇨🇳
Lingchuan Center for Disease Control and Prevention, Lingchuan, Guangxi, China
🇨🇳Quanzhou Center for Disease Control and Prevention, Quanzhou, Guangxi, China
🇨🇳Xing'an Center for Disease Control and Prevention, Xing'an, Guangxi, China
Phase III Study Comparing the Immunogenicity of 9-valent HPV Recombinant Vaccine and Gardasil-9
Phase 3
Active, not recruiting
- Conditions
- Genital WartVINCINPapillomavirus InfectionsCervical Cancer
- Interventions
- Biological: GARDASIL ®9Biological: Zerun HPV-9
- First Posted Date
- 2022-10-14
- Last Posted Date
- 2022-10-28
- Lead Sponsor
- Shanghai Zerun Biotechnology Co.,Ltd
- Target Recruit Count
- 1200
- Registration Number
- NCT05580341
- Locations
- 🇨🇳
GuangXi Center for Diseases Control and Prevention, Nanning, Guangxi, China
Evaluation of Safety and Immunogenicity of the Recombinant ZR202-CoV and ZR202a-CoV Vaccines in Adults.
Phase 1
Active, not recruiting
- Conditions
- SARS-CoV-2 InfectionCOVID-19
- Interventions
- Biological: ZR202a-CoVBiological: Comirnaty®Biological: ZR202-CoV
- First Posted Date
- 2022-08-05
- Last Posted Date
- 2023-04-20
- Lead Sponsor
- Shanghai Zerun Biotechnology Co.,Ltd
- Target Recruit Count
- 60
- Registration Number
- NCT05490108
- Locations
- 🇲🇱
Center for Vaccine Development-Mali, Bamako, Mali
Safety and Immunogenicity of Recombinant SARS-CoV-2 Spike Protein Vaccine (CHO Cell) for the Prevention of COVID-19
Phase 1
Active, not recruiting
- Conditions
- COVID-19
- Interventions
- Biological: ZR-202-CoVOther: Placebo
- First Posted Date
- 2022-04-06
- Last Posted Date
- 2023-04-19
- Lead Sponsor
- Shanghai Zerun Biotechnology Co.,Ltd
- Target Recruit Count
- 84
- Registration Number
- NCT05313022
- Locations
- 🇨🇳
Clinical Trial Institution for Anning First Hospital, Kunming, Yunan, China
Phase II Clinical Trial of Recombinant SARS-CoV-2 Spike Protein Vaccine (CHO Cell) for the Prevention of COVID-19
Phase 2
Active, not recruiting
- Conditions
- COVID-19
- Interventions
- Biological: 202-CoV standard doseBiological: 202-CoV low adjuvant doseBiological: 202-CoV low antigen doseBiological: Placebo
- First Posted Date
- 2021-08-04
- Last Posted Date
- 2023-04-19
- Lead Sponsor
- Shanghai Zerun Biotechnology Co.,Ltd
- Target Recruit Count
- 528
- Registration Number
- NCT04990544
- Locations
- 🇨🇳
Xiangcheng Center for Disease Control and Prevention, Xuchang, China
Phase I Clinical Trial of Recombinant SARS-CoV-2 Spike Protein Vaccine (CHO Cell) for the Prevention of COVID-19
Phase 1
Active, not recruiting
- Conditions
- COVID-19
- Interventions
- Other: PlaceboBiological: 202-CoV low antigen doseBiological: 202-CoV low adjuvant doseBiological: 202-CoV standard dose
- First Posted Date
- 2021-07-29
- Last Posted Date
- 2023-04-19
- Lead Sponsor
- Shanghai Zerun Biotechnology Co.,Ltd
- Target Recruit Count
- 72
- Registration Number
- NCT04982068
- Locations
- 🇨🇳
Xiangcheng Center for Disease Control and Prevention, Xuchang, China
Lot Consistency Clinical Trial of Bivalent HPV Vaccine in 9 to 30 Years Old Healthy Females
Phase 3
Completed
- Conditions
- HPV Infection
- Interventions
- Biological: Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine (Pichia pastoris)
- First Posted Date
- 2021-07-16
- Last Posted Date
- 2023-04-13
- Lead Sponsor
- Shanghai Zerun Biotechnology Co.,Ltd
- Target Recruit Count
- 1100
- Registration Number
- NCT04965350
- Locations
- 🇨🇳
Mianyang Center for Disease Control and Prevention, Mianyang, Sichuan, China
A Study of Safety and Primary Immunogenicity of 9-valent HPV Recombinant Vaccine
Phase 1
Completed
- Conditions
- HPV Infections
- Interventions
- Biological: HPV VaccineDrug: Placebo
- First Posted Date
- 2019-04-03
- Last Posted Date
- 2023-04-13
- Lead Sponsor
- Shanghai Zerun Biotechnology Co.,Ltd
- Target Recruit Count
- 90
- Registration Number
- NCT03900572
- Locations
- 🇨🇳
Sichuan Provincial Center for Disease Prevention and Control, Chengdu, Sichuan, China
Immunogenicity and Safety of Human Papillomavirus (HPV)-16/18 Vaccine in Healthy Females
Phase 2
Completed
- Conditions
- Human Papillomavirus
- Interventions
- Biological: HPV vaccineBiological: Placebo
- First Posted Date
- 2016-04-15
- Last Posted Date
- 2023-04-13
- Lead Sponsor
- Shanghai Zerun Biotechnology Co.,Ltd
- Target Recruit Count
- 1200
- Registration Number
- NCT02740790
- Locations
- 🇨🇳
GuangXi Center for Diseases Control and Prevention, Nanning, Guangxi, China
Evaluating the 2-dose Immunization Schedule of Human Papillomavirus (HPV)-16/18 in Adolescent Females
Phase 2
Completed
- Conditions
- Human PapillomavirusCervical Intraepithelial NeoplasiaPersistent Infection
- Interventions
- Biological: HPV-16/18 vaccine
- First Posted Date
- 2016-04-15
- Last Posted Date
- 2023-04-13
- Lead Sponsor
- Shanghai Zerun Biotechnology Co.,Ltd
- Target Recruit Count
- 900
- Registration Number
- NCT02740777
- Locations
- 🇨🇳
Hezhou Center for Disease Prevention and Control, Hezhou, Guangxi, China
🇨🇳Zhongshan Center for Disease Prevention and Control, Zhongshan, Guangxi, China
© Copyright 2025. All Rights Reserved by MedPath